Bloomberg -- Elan Corp. and Biogen Idec Inc. asked U.S. and EU regulators for permission to change the label of the multiple sclerosis medicine Tysabri to tell doctors and patients about a test that can predict the odds of getting a deadly brain illness from the drug.
